Clinical Trial Update: The Role of Pioglitazone in Vascular Transcriptional Remodeling [Phase 4]

View source ↗

Summary

Phase 4 trial update exploring pioglitazone's role in vascular transcriptional remodeling for myocardial reperfusion injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Reperfusion Injury

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: University of Campinas, Brazil | Conditions: Myocardial Reperfusion Injury | Phase 4 | Status: UNKNOWN